Major Indian Pharmas Seek Deals With MNCs To Collaborate On Phase III Work (India)
This article was originally published in PharmAsia News
Major Indian pharmaceutical companies, in an apparent strategy change, plan to seek collaboration agreements with multinational drug makers on Phase III research. Indian firms such as Dr. Reddy's Laboratory, Nicholas Piramat, Sun Pharma and Wockhardt are attempting to add to their pipelines of new chemical entities. The strategy includes commercializing drugs in the West under contracts that would give the Indian firms larger milestone payments. Analysts say the strategy change is driven by a need for new revenue streams. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.